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1535Does Speckle Tracking
Really Improve Diagnosis
and Risk Stratiﬁcation in
Patients With HF With
Normal EF?The pathophysiology of heart failure (HF) with
normal ejection fraction (EF) is complex; echocardi-
ography may add further confusion, especially when
it focuses on one aspect of cardiac function to the
exclusion of all others. Among 219 patients with a
LVEF >45% and plasma N-terminal pro–B-type
natriuretic peptide (NT-proBNP) >400 ng/l who
were randomized in PARAMOUNT (The Prospective
comparison of ARNI with ARB on Management Of
heart failUre with preserved ejectioN fraction Trial),
Kraigher-Krainer et al. (1) showed that most of these
patients had reduced longitudinal or circumferential
LV systolic function measured by 2-dimensional
speckle tracking compared with control subjects or
patients with hypertension. The severity of systolic
dysfunction was closely related to plasma NT-
proBNP, which is a powerful prognostic marker (2).
Neither E0 nor left atrial volume (LAVI), which are
popular measurements of diastolic dysfunction, were
strongly associated with NT-proBNP.
We found a broadly similar association between
global longitudinal strain (GLS) by speckle tracking
and NT-proBNP among 313 outpatients with sus-
pected heart failure who had a LVEF >50% (3).
However, in our study, GLS was a weak pre-
dictor of outcomes using univariable analysis; only
inferior vena cava dimension, serum urea, and NT-
proBNP were independent predictors on multivari-
able analysis.
The PARAMOUNT and TOPCAT (Treatment of Pre-
served Cardiac Function Heart Failure With an Aldo-
sterone Antagonist) studies have begun to establish
raised plasma concentrations of natriuretic peptides
as a key selection criterion for clinical trials of
HF with normal LVEF and as an integral part of its
diagnosis.
Similar to echocardiography, NT-proBNP alone
is insufﬁcient for a diagnosis of heart failure; it
is merely a measure of the severity of cardiac
dysfunction. However, the activation of this counter-
regulatory system, which is designed to correct con-
gestion, is powerful evidence of disease.
Should echocardiography now be relegated purely
to excluding low LVEF or valve disease as the cause
of heart failure, with the diagnosis of heart failuremade by clinical evaluation informed by NT-proBNP
and with knowledge of the patient’s body mass in-
dex, heart rhythm and renal function? Although
the answer is probably “yes,” more experience and
training in the use of both natriuretic peptides and
echocardiography are still required.
A deeper understanding of echocardiographic
phenotyping, especially of right heart function (4),
will provide much greater diversity of therapeutic
targets than the current crude separation into HF
with reduced EF, preserved EF, and valve disease.
Echocardiography will continue to have an essential
role in diagnosing the cause of HF, although it is
no longer required to conﬁrm its presence.*Pierpaolo Pellicori, MD
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2013;6:16–28.REPLY: Does Speckle Tracking Really
Improve Diagnosis and Risk Stratiﬁcation
in Patients With HF With Normal EF?We appreciate the letter from Dr. Pellicori and col-
leagues regarding our recent paper, which described
the prevalence and correlates of abnormal strain as
a measure of left ventricular (LV) systolic function
in heart failure with preserved ejection fraction
(HFpEF). As pointed out by Pellicori and colleagues,
our analysis did not seek to evaluate the prognostic
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1536relevance of this measure of LV systolic function (1).
The prognostic utility of an impaired strain in HFpEF
and its performance relative to other imaging
markers and biomarkers, such as N-terminal pro–B-
type natriuretic peptide (NT-proBNP), will need to be
deﬁned in adequately powered studies with pro-
spectively ascertained and adjudicated clinical end-
points. Furthermore, to better understand how subtle
abnormalities in systolic function, identiﬁed by these
deformation measures, affects the clinical status of
patients with HFpEF, future studies will also need to
characterize the physiological and hemodynamic
implications of impaired strain.
We agree with Dr. Pellicori and colleagues that
the primary role of echocardiography in establishing
the diagnosis of HFpEF is in the quantiﬁcation of
left ventricular ejection fraction (LVEF) in patients
with signs and symptoms of heart failure. However,
similar to NT-proBNP (2), several echocardiographic
measures can provide the clinician with additional
information regarding patient risk within this het-
erogeneous syndrome. These measures include LV
mass and geometry, left atrial size, and the presence
of pulmonary hypertension (3–5). Whether LV strain
will be added to this list remains to be determined.
Ultimately, the major utility of echocardiography and
biomarkers in this syndrome may be to better identify
pathophysiologically relevant patient subgroups in
whom targeted therapies can be evaluated (6).*Amil M. Shah, MD, MPH
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